pf562271  (MedChemExpress)

Journal: World Journal of Gastroenterology

Article Title: FBP1 as a key regulator of focal adhesion kinase-mediated hepatic stellate cell activation: Multi-omics and experimental validation

doi: 10.3748/wjg.v31.i28.107361

Figure Lengend Snippet: Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and PF562271 (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.

Article Snippet: LX-2 cells, an activated human HSCs line[ ], were treated with varying concentrations of the FAK inhibitor PF562271 (2.5 μM, 5 μM, 10 μM) based on the IC 50 provided by MCE (MedChem Express).

Techniques: Gene Expression, Expressing

Journal: World Journal of Gastroenterology

Article Title: FBP1 as a key regulator of focal adhesion kinase-mediated hepatic stellate cell activation: Multi-omics and experimental validation

doi: 10.3748/wjg.v31.i28.107361

Figure Lengend Snippet: Proteomics analysis of differential protein expression. A: Principal component analysis (PCA) of normalized protein counts PCA of protein expression across normal, carbon tetrachloride (CCl₄) and PF562271 (PF) conditions. The first principal component (PC1) explains 39.3% of variance, while PC2 explains 9.5%. The three conditions show clear separation; B: Volcano plot showing differentially expressed proteins between the normal and CCl₄ groups. Significant proteins ( P < 0.05, log2 fold change > 1 or < -1) are highlighted; C: Volcano plot comparing the CCl₄ and PF groups. Significant proteins are marked, indicating differential expression between these two conditions ( P < 0.05); D: Mfuzz clustering of protein expression profiles. Clusters 1, 3, and 4 are shown, highlighting distinct expression trends in normal, CCl₄, and PF conditions; E: UpSet plot showing overlaps of differentially expressed proteins between comparisons (normal vs CCl₄, CCl₄ vs PF) and clusters from Mfuzz analysis; F: Venn diagram showing overlap of differentially expressed proteins between the normal vs CCl₄ and CCl₄ vs PF groups. The diagram indicates unique and shared proteins across the conditions.

Article Snippet: LX-2 cells, an activated human HSCs line[ ], were treated with varying concentrations of the FAK inhibitor PF562271 (2.5 μM, 5 μM, 10 μM) based on the IC 50 provided by MCE (MedChem Express).

Techniques: Expressing, Quantitative Proteomics

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Reconstructing signaling networks using biosensor barcoding

doi: 10.1007/978-1-0716-3834-7_13

Figure Lengend Snippet: Inhibitors

Article Snippet: Drug Name Target Stock Concentration (mM) Working Concentration (μM) Source Identifier Gefitinib EGFR 1 1 Cayman 13166 PF562271 FAK 10 1 AdipoGen SYN-1064 ZSTK474 PI3K 10 1 Cell Signaling 13213 GDC-0994 ERK 10 1 APExBIO Technology B5817 BAPTA-AM Calcium 10 10 Selleck S7534 Y27632 ROCK 10 10 Enzo Life Sciences ALX-270–333 Dasatinib Src 10 1 Cayman 11498 LY2584702 S6K 1 1 Selleck S7698 Open in a separate window Inhibitors.

Techniques: Concentration Assay